Among the concluded cases, there are 299,689 civil cases, 15,048 administrative cases and 38,051 criminal cases. (Source: China IP Right News )

According to statistics, China received 928,000 patent applications in 2014, ranking first in the world for four consecutive years; accepted 2,285,400 applications for trademark registration, having been ranking the first for 13 consecutive years. While China ranks the 29th of the Global Innovation Index Report, which obviously does not match with the above-mentioned IP achievement of China. It addresses the challenge for China to innovate, as leading the filing number is not China’s goal; improving innovation quality becomes their top priority.

Nevertheless, the report also suggests China’s improvement in innovation quality, the country outperformed most of the developing countries and topped in the indexes of talent cultivation, innovation environment, market maturity, commercial maturity, knowledge and technology innovation output among these countries. Many in the industry believes it’s a reflection of China’s transform from ‘innovation quantity’ to ‘innovation quality’. (Source: China Intellectual Property News)

The Opinions took market-oriented principles, strengthening guidance, and actively promotion and actual effect as 4 basic principles, namely, China should use the role of IP as an incentive for innovation and entrepreneurial activity, and fully mobilize market forces to form the entrepreneurship incentives and benefit distribution mechanisms as well as efficient allocation of factors of innovation and entrepreneurship; to form the guiding role of IP on innovation and entrepreneurial activity, innovate the service models and processes, improve the level of innovation and entrepreneurship development through more effective means such as patent navigation; adhere to the principles of policy coordination, active movement, open and cooperation to establish the IP innovation supporting policy and entrepreneurship service system with government guidance, market drive and social participation, to create positive atmosphere for mass entreprenurship and innovation; establish coordination and linkage mechanism to meet the needs of innovation and entrepreneurial activity, strengthen the implementation of assessment and feedback, and constantly improve the policy environment, the institutional environment and public service system for innovation, and entrepreneurship. (Source: China Intellectual Property News)

Among the invention patent applications, 610,000 were filed by domestic applicants, up 24.9%; 99,000 were from overseas, up 5.1%. Among the domestic invention patent applications, 492,000 were service applications, accounted for 80.7%; 118,000 were non-service applications, accounted for 19.3%

Among the invention patents granted, 181,000 were domestic, up 52.5%; 67,000 were from overseas, up 31.1%. Among the domestic invention patents, 164,000 were service invention patents, accounted for 90.6%; 17,000 were non-service invention patents, accounted for 9.4%.

INTA (The International Trademark Association) is a worldwide not-for-profit association of trademark owners and professionals dedicated to supporting trademarks and intellectual property in order to protect consumers and to promote fair and effective global commerce. INTA’s members are more than 6,500 organizations from 190 countries. The Association's member organizations represent some 30,000 trademark professionals and include brand owners from major corporations as well as small- and medium-sized enterprises, law firms and nonprofits. There are also government agency members as well as individual professor and student members. INTA undertakes advocacy work throughout the world to advance trademarks and offers educational programs and informational and legal resources of global interest.

Bio links for the lawyers in the new appointment:

Mr. Yongbo Li:
http://www.unitalen.com/servlet/Node?Node=21462

Mr. Lei Zhao:
http://www.unitalen.com/servlet/Node?node=38555

Rooted from Institute of Biophysics - Chinese Academy of Sciences, JYR had developed a diagnostic kit and its methods for the testing of aerobic organism in vaginal discharge, which was granted with ZL2009 1 0244267.4 Invention Patent back in 2012. However, the defendant, Anhui Tuote Biological Engineering Co. Ltd. (Tuote) submitted a tender and won the contract with Women’s Hospital of Zhejiang University, in which Tuote will supply “aerobic organism in vaginal discharge and BV 5 items testing kit” to the hospital. Following this, JYR sued Tuote for infringement of its above-mentioned patent right.

The debates in the court are mainly on the following three issues:

1.Whether ‘β-葡萄糖醛酸苷酶 (β-Glucuronidase)’ is the same substance as ‘β-葡萄糖醛酸酶(β-Glucuronidase)
2.Whether ‘5-溴-4-氯-3-吲哚-β-葡萄糖醛酸钠盐（5-Bromo-4-chloro-3-indolyl-beta-glucuronide sodium salt）’ is the same substance as ‘5-溴-4-氯-3-吲哚-β-D-葡萄糖醛酸苷钠盐 (5-Bromo-4-Chloro-3-Indolyl Beta-D-Glucuronide Sodium Salt) ’;
3.Whether ‘甘氨酰精氨酸-β-萘胺（Glycyltryptophan-β-naphthyl amine）’ has the same effect as ‘甘氨酰精氨酸-4-甲氧基-β-萘胺（glycyl-arginyl-4-methoxyl-β-naphthylamide)

As requested by the plaintiff, Professor Qingcheng Wen, who is a biochemistry researcher of Peking Union Medical College as well as one of the developers of Enzymatic testing kit methods in China, acted as the professional advisor in this case. He’s provided his opinion regarding the above questions:

1.‘β-葡萄糖醛酸苷酶’ and ‘β-葡萄糖醛酸酶’ should be the same substance as they are different translations to the same English word “β-Glucuronidase”.
2.2. ‘5-溴-4-氯-3-吲哚-β-葡萄糖醛酸苷钠盐(5-Bromo-4-chloro-3-indolyl-beta-glucuronide sodium salt)’ should be the same substance as ‘5-溴-4-氯-3-吲哚-β-D-葡萄糖醛酸苷钠盐 (5-Bromo-4-Chloro-3-Indolyl Beta-D-Glucuronide Sodium Salt) ’, as it has two isomers: D ( right handed) and L (left handed), which are interchangeable in aqueous solution；
3.3. The reaction mechanism of ‘甘氨酰精氨酸-β-萘胺（Glycyltryptophan-β-naphthyl amine）and ‘甘氨酰精氨酸-4-甲氧基-β-萘胺（Glycyltryptophan - 4-methoxy -β-naphthyl amine’ are the same, which is coagulase hydrolyzed glycyl-arginine amine salt in vaginal discharge and it will display red or purple color with use of chromogenic agent; ‘4-methoxy’ acts as modification without reaction.

At the end, the court reached the verdict that Tuote’s product has the same technological characteristics as all of those recorded for the plaintiff’s patent and therefore had constituted infringement of patent right.